ClinicalTrials.gg
RecruitingNCT05706129Updated Aug 11, 2026

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC) and Colorectal Cancer (CRC), sponsored by Lumara Bio Oncologics GmbH. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Lumara Bio Oncologics GmbH · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 201 studies in Carcinoma, Renal Cell with a site in France — 35 open to participants now, 57 under way, 18 of them phase 3. Carcinoma, Renal Cell · France.

Planned enrollment
68th of 170
270 · median 165
Started
2023
with 16 others
Phase 1/2
13 of 201
5 open now
Primary completion
2027-06
later than 36 of 56 live
Registered
174th of 201
by date

Among the 201 studies in Carcinoma, Renal Cell with a site in France, this one is the 68th largest by planned enrollment of the 170 interventional ones that give a count, is one of 17 that started in 2023, is one of 13 in phase 1/2, reaches primary completion later than 36 of the 56 other live ones, and was the 174th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

35 of the 201 studies in Carcinoma, Renal Cell with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Carcinoma, Renal Cell with a site in France, or all of them as a file.
02

Study summary

The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) [maximum tolerated dose (MTD) or lower dose] for [177Lu]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of [177Lu]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between [68Ga]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess [68Ga]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC.

03

Conditions studied

  • Clear Cell Renal Cell Cancer (ccRCC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Colorectal Cancer (CRC)
  • Urothelial Carcinoma (UC)
  • Indeterminate Renal Mass (IDRM)
  • Muscle Invasive Bladder Cancer (MIBC)
  • Head and Neck Cancer (H&N)
  • Triple Negative Breast Cancer (TNBC)
  • Squamous Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A, B, and C:

  • Written , dated and signed by the patient prior to any study-specific procedure.
  • Part B and C are not conducted in the United States of America.
  • Has or cytologically confirmed, unresectable locally advanced or solid tumors of:
  • Clear cell renal cell cancer (ccRCC) - participants must have received at least one line containing Tyrosine kinase inhibitor (TKI) treatment and at least one line containing treatment in metastatic setting, meaning at least two in metastatic setting.
  • Pancreatic ductal adenocarcinoma (PDAC) - participants must have received at least one line of platinum- and/or gemcitabine-based regimen.
  • Colorectal cancer (CRC) - participants must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-Vascular Endothelial Growth Factor (VEGF) or anti-Epidermal Growth Factor Receptor (EGFR).
  • Participants with CRC or PDAC: availability of fresh , OR an archival biopsy/surgical specimen of the tumor (preferably, taken after last prior line of therapy).
  • For Part B and C only: Urothelial cancer (UC) patients must have received all available standard of care if eligible, including one line of platinum-based chemotherapy, enfortumab vedotin and pembrolizumab.
  • Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (computed tomography / magnetic resonance imaging (CT/MRI)) documented within 4 weeks prior to the [68Ga]Ga-DPI-4452 administration.
  • per (RECIST) v1.1.

Part D:

Participants with imaging evidence of a single indeterminate renal mass (IDRM) of ≤ 7 cm in largest diameter (tumor stage cT1) on any conventional diagnostic imaging technique, suspicious for ccRCC and planned for total or partial nephrectomy, or interventional diagnostic (cystoscopy and retrograde pyelography or biopsy) within 90 days from planned [68Ga]Ga-DPI-4452 administration.

Part E:

Regardless of lines of treatment, participants with histologically or cytologically confirmed progressive, unresectable locally advanced or metastatic solid tumors of

  • UC, including MIBC
  • H\&N cancer
  • TNBC
  • Squamous NSCLC
  • Any other indication with confirmed carbonic anhydrase IX (CA IX) expression excluding ccRCC, PDAC and CRC, upon Sponsor agreement.

Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (CT/MRI) documented within 4 weeks prior to the [68Ga]Ga-DPI-4452 administration (for scans dated more than 4 weeks prior to D1, the Sponsor should be contacted to assess conventional imaging suitability)

Exclusion criteria

Exclusion Criteria:

  • Any major surgery within 12 weeks before enrolment.
  • Inability to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan.

Part A:

  • Has known to the active substance, to any of the of the DPI-4452, or to radiographic contrast agents.
  • Bladder outflow obstruction or unmanageable urinary incontinence.
  • Participants who have not had resolution of toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and/or stable Grade 2 sensory neuropathy, according to National Cancer Institute [NCI-CTCAE]).
  • Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-4452.
  • Previous Carbonic anhydrase (CA) IX-targeting treatment.
  • Prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow, as judged by the Investigator.

Part B and Part C:

  • Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
  • Bladder outflow obstruction or unmanageable urinary incontinence.
  • Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, active clinically significant cardiac disease, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, or stable Grade 2 sensory neuropathy, according to NCI-CTCAE).
  • Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months prior to injection of [68Ga]Ga-DPI-4452.
  • Any previous CA IX-targeting treatment for non-oncological indication within 3 months prior to the [177Lu]Lu-DPI-4452 infusion; any previous CA IX-targeting treatment for any oncological indication.
  • Participants who received any systemic antineoplastic therapy for the underlying disease and/or other agents within a period which is ≤5 half-lives or ≤4 weeks (whichever is shorter).
  • Inflammatory bowel disease (e.g Crohn's disease, ulcerative colitis, etc).

Part D:

  • Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
  • Any previous CA IX-targeting treatment within 3 months prior to the [68Ga]Ga-DPI-4452 injection.
  • Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-4452.
  • Malignant disease, other than that being treated in this study. Exceptions include the following: that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy.
  • Ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) within 2 weeks (or 5 half-lives, whichever is longer) prior to the [68Ga]Ga-DPI-4452 injection.

Part E:

  • Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
  • Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-4452.
  • Any previous CA IX-targeting treatment within 3 months prior to [68Ga]Ga-DPI-4452 injection.
  • EBRT to more than 25% of the bone marrow, as judged by the Investigator.
  • Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy.

Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Part A: [68Ga]Ga-DPI-4452

    Participants will receive \[68Ga\]Ga-DPI-4452, a single dose on Day 1.

    Drug: [68Ga]Ga-DPI-4452

  • Experimental
    Part B: [177Lu]Lu-DPI-4452

    Participants will receive a single dose of \[68Ga\]Ga-DPI-4452, at screening then escalating doses of \[177Lu\]Lu-DPI-4452, on Day 1 of each (Q4W or Q6W) cycle and RP2D will be determined.

    Drug: [68Ga]Ga-DPI-4452 · Drug: [177Lu]Lu-DPI-4452

  • Experimental
    Part C: [177Lu]Lu-DPI-4452

    Participants will receive a single dose of \[68Ga\]Ga-DPI-4452, at screening and RP2D dose of \[177Lu\]Lu-DPI-4452, on Day 1 of each cycle (Q4W or Q6W) the treatment period.

    Drug: [68Ga]Ga-DPI-4452 · Drug: [177Lu]Lu-DPI-4452

  • Experimental
    Part D: [68Ga]Ga-DPI-4452

    Participants will receive \[68Ga\]Ga-DPI-4452, a single dose on Day 1.

    Drug: [68Ga]Ga-DPI-4452

  • Experimental
    Part E: [68Ga]Ga-DPI-4452

    Participants will receive \[68Ga\]Ga-DPI-4452, a single dose on Day 1.

    Drug: [68Ga]Ga-DPI-4452

Interventions

  • \[68Ga\]Ga-DPI-4452, administered as IV injection.

  • Drug[177Lu]Lu-DPI-4452

    \[177Lu\]Lu-DPI-4452, administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 7

  2. Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    Time frame: Cycle 1(each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule)

  3. Part C: Objective Response Rate (ORR)

    Time frame: Up to 81 months

  4. Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM

    Time frame: Day 1

  5. Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging

    Time frame: Day 1

Secondary outcomes

  1. Part A, B, and C: Concentration of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Blood and Plasma

    Pharmacokinetics (PK) will be evaluated in blood and plasma for radioactivity of \[68Ga\]Ga-DPI-4452 and \[177Lu\]Lu-DPI-4452.

    Time frame: Part A: Pre-dose and at multiple time points up to 4 hours post-dose on Day 1; Parts B and C: Pre-dose and at multiple time points up to 72 hours post-dose of Cycles 1, 2 and 3 (84 days) (each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks)

  2. Parts A, B, and C: Concentration of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Urine

    PK will be evaluated in urine for radioactivity of \[68Ga\]Ga-DPI-4452 and \[177Lu\]Lu-DPI-4452.

    Time frame: Part A: Pre-dose and at multiple time points up to 4 hours post-dose on Day 1; Parts B and C: Pre-dose and at multiple time points up to 48 hours post-dose of Cycle 1 (each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule)

  3. Part A: Radioligand [68Ga]Ga-DPI-4452 PET Scan Time-Window for Optimal Imaging

    Time frame: Day 1

  4. Part B: Objective Response Rate (ORR)

    Time frame: Up to 81 months

  5. Parts B and C: Progression Free Survival (PFS) Rate at 6 Months

    Time frame: 6 months

  6. Parts B and C: Progression Free Survival (PFS)

    Time frame: Up to 81 months

  7. Parts B and C: Overall Survival (OS)

    Time frame: Up to 81 months

  8. Parts B and C: Duration of Response (DoR)

    Time frame: Up to 81 months

  9. Parts B and C: Disease Control Rate (DCR)

    Time frame: Up to 81 months

  10. Parts B, C, D, and E: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 81 months

  11. Parts A, B, C, and E: Number of Positive Tumor Lesions Detected by Imaging

    Time frame: Part A and E: Day 1; Part B and C: Baseline

  12. Parts A, B, and C: Dosimetry [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452

    Whole body effective dose will be calculated using the PET scan.

    Time frame: Part A: Day 1; Parts B and C: Cycle 1 (each cycle= 28 days)

  13. Part D: Assessment of Diagnostic Accuracy of [68Ga]Ga-DPI-4452 PET imaging

    Assessment by sensitivity, specificity, positive predicted value (PPV) and negative predicted value (NPV) of \[68Ga\]Ga-DPI-4452 PET imaging compared to histology.

    Time frame: Day 1

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2027, 51 months after the start.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 51 months is below that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 31, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2029
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05706129
Lead sponsor
Lumara Bio Oncologics GmbH
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Mar 14, 2023
Primary completion
Jun 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 11, 2026

Study contacts

Lumara Bio Oncologics GmbH
Contact
info-itm91_94-phase1_2@itm-radiopharma.com
(+49) 89 329898 66000

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion